Skip to main content
Erschienen in: Lung 6/2013

01.12.2013

Assessment of Pathologically Diagnosed Patients with Castleman’s Disease associated with Diffuse Parenchymal Lung Involvement Using the Diagnostic Criteria for IgG4-Related Disease

verfasst von: Takaaki Ogoshi, Takashi Kido, Kazuhiro Yatera, Keishi Oda, Toshinori Kawanami, Hiroshi Ishimoto, Noriho Sakamoto, Arisa Sano, Chiharu Yoshii, Shohei Shimajiri, Hiroshi Mukae

Erschienen in: Lung | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

IgG4-related disease (IgG4RD) is a recently recognized disease entity. Differentiating IgG4RD from plasma cell type Castleman’s disease (PCD) is important but also difficult using only pathological findings. In addition, little is known about the association between these two diseases with diffuse parenchymal lung involvement.

Methods

We analyzed the serum IgG4 levels and the ratio of IgG4/IgG-positive plasmacytes in the lung and lymph node specimens of eight patients previously pathologically diagnosed of PCD with diffuse parenchymal lung involvement (DL-PCD). We also compared the clinical and laboratory findings observed in these patients.

Results

Six of the eight patients exhibited abundant IgG4-positive plasmacytes in the lung and lymph node tissues and elevated serum IgG4 levels, thereby fulfilling the diagnostic criteria of IgG4RD with DL (DL-IgG4RD) in addition to having obstructive phlebitis and massive lymphoplasmacytic infiltration with fibrosis. However, three of these six patients exhibited higher levels of serum interleukin-6 and were still diagnosed with DL-PCD. Accordingly, three of these eight patients were considered as IgG4RD with DL (DL-IgG4RD), and the other five patients were ultimately given a diagnosis of DL-PCD. These two diseases have different characteristics in terms of age, symptoms, serum levels of C-reactive protein, and IgA, complicating allergic disorders, response to corticosteroids, and prognosis.

Conclusions

This is the first report to show a high prevalence of DL-IgG4RD in DL-PCD patients, although additional large investigations are necessary. Clinical and laboratory findings are important for distinguishing between these two diseases in other organs, as previously described.
Literatur
2.
3.
Zurück zum Zitat Cheuk W, Yuen HK, Chu SY et al (2008) Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 32:671–681CrossRefPubMed Cheuk W, Yuen HK, Chu SY et al (2008) Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 32:671–681CrossRefPubMed
4.
Zurück zum Zitat Masaki Y, Dong L, Kurose N et al (2009) Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 68:1310–1315CrossRefPubMed Masaki Y, Dong L, Kurose N et al (2009) Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 68:1310–1315CrossRefPubMed
5.
Zurück zum Zitat Smyrk TC (2011) Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol 23:74–79CrossRefPubMed Smyrk TC (2011) Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol 23:74–79CrossRefPubMed
6.
Zurück zum Zitat Zen Y, Nakanuma Y (2010) IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 34:1812–1819CrossRefPubMed Zen Y, Nakanuma Y (2010) IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 34:1812–1819CrossRefPubMed
7.
Zurück zum Zitat Fujinaga Y, Kadoya M, Kawa S et al (2010) Characteristic findings in images of extra-pancreatic lesions associated with autoimmune pancreatitis. Eur J Radiol 76:228–238CrossRefPubMed Fujinaga Y, Kadoya M, Kawa S et al (2010) Characteristic findings in images of extra-pancreatic lesions associated with autoimmune pancreatitis. Eur J Radiol 76:228–238CrossRefPubMed
8.
Zurück zum Zitat Matsui S, Taki H, Shinoda K et al (2012) Respiratory involvement in IgG4-related Mikulicz’s disease. Mod Rheumatol 22:31–39CrossRefPubMed Matsui S, Taki H, Shinoda K et al (2012) Respiratory involvement in IgG4-related Mikulicz’s disease. Mod Rheumatol 22:31–39CrossRefPubMed
9.
Zurück zum Zitat Matsui S, Hebisawa A, Sakai F et al (2013) Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respirology 18:480–487CrossRefPubMed Matsui S, Hebisawa A, Sakai F et al (2013) Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respirology 18:480–487CrossRefPubMed
10.
Zurück zum Zitat Ryu JH, Sekiguchi H, Yi ES (2012) Pulmonary manifestations of immunoglobulin G4-related sclerosing disease. Eur Respir J 39:180–186CrossRefPubMed Ryu JH, Sekiguchi H, Yi ES (2012) Pulmonary manifestations of immunoglobulin G4-related sclerosing disease. Eur Respir J 39:180–186CrossRefPubMed
11.
Zurück zum Zitat Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 9:822–830CrossRefPubMed Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 9:822–830CrossRefPubMed
12.
Zurück zum Zitat Frizzera G (1988) Castleman’s disease and related disorders. Semin Diagn Pathol 5:346–364PubMed Frizzera G (1988) Castleman’s disease and related disorders. Semin Diagn Pathol 5:346–364PubMed
13.
Zurück zum Zitat Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H (1985) Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 16:162–172CrossRefPubMed Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H (1985) Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 16:162–172CrossRefPubMed
14.
Zurück zum Zitat Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360–1367PubMed Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360–1367PubMed
15.
Zurück zum Zitat Nishimoto N (2005) Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 28:221–230CrossRefPubMed Nishimoto N (2005) Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 28:221–230CrossRefPubMed
16.
Zurück zum Zitat Ishida F, Kitano K, Kobayashi H, Saito H, Kiyosawa K (1997) Elevated IgG4 levels in a case with multicentric Castleman’s disease. Br J Haematol 99:981–982PubMed Ishida F, Kitano K, Kobayashi H, Saito H, Kiyosawa K (1997) Elevated IgG4 levels in a case with multicentric Castleman’s disease. Br J Haematol 99:981–982PubMed
17.
Zurück zum Zitat Kojima M, Nakamura N, Motoori T et al (2010) Castleman’s disease of the retroperitoneum: with special reference to IgG4-related disorder. J Clin Exp Hematop 50:39–44CrossRefPubMed Kojima M, Nakamura N, Motoori T et al (2010) Castleman’s disease of the retroperitoneum: with special reference to IgG4-related disorder. J Clin Exp Hematop 50:39–44CrossRefPubMed
18.
Zurück zum Zitat Sato Y, Kojima M, Takata K et al (2010) Multicentric Castleman’s disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol 63:1084–1089CrossRefPubMed Sato Y, Kojima M, Takata K et al (2010) Multicentric Castleman’s disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol 63:1084–1089CrossRefPubMed
19.
Zurück zum Zitat Shrestha B, Sekiguchi H, Colby TV et al (2009) Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol 33:1450–1462CrossRefPubMed Shrestha B, Sekiguchi H, Colby TV et al (2009) Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol 33:1450–1462CrossRefPubMed
20.
Zurück zum Zitat Strehl JD, Hartmann A, Agaimy (2011) A Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol 64:237–243CrossRefPubMed Strehl JD, Hartmann A, Agaimy (2011) A Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol 64:237–243CrossRefPubMed
21.
Zurück zum Zitat Ogoshi T, Yatera K, Nagata S et al (2011) A case of multicentric Castleman disease with massive infiltration of plasmacytes presenting IgG4. JJRS 49:437–442 Ogoshi T, Yatera K, Nagata S et al (2011) A case of multicentric Castleman disease with massive infiltration of plasmacytes presenting IgG4. JJRS 49:437–442
22.
Zurück zum Zitat Sato Y, Kojima M, Takata K et al (2009) Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol 22:589–599CrossRefPubMed Sato Y, Kojima M, Takata K et al (2009) Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman’s disease. Mod Pathol 22:589–599CrossRefPubMed
23.
Zurück zum Zitat Webb WR, Muller NL, Naidich DP (2001) Illustrated glossary of high-resolution computed tomography term. High-resolution CT of the lung, 3rd edn. Lippincott Williams & Wilkins, Philadelphia Webb WR, Muller NL, Naidich DP (2001) Illustrated glossary of high-resolution computed tomography term. High-resolution CT of the lung, 3rd edn. Lippincott Williams & Wilkins, Philadelphia
24.
Zurück zum Zitat Flendrig JA, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119 Flendrig JA, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119
25.
Zurück zum Zitat Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683CrossRefPubMed Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683CrossRefPubMed
26.
Zurück zum Zitat Jo JH, Park YS, Jeon YK, Nam SJ, Huh J (2011) Comparison of plasma cell type of Castleman’s disease and IgG4-related sclerosing disease: a histopathological and immunohistochemical study. Pathobiology 78:227–232CrossRefPubMed Jo JH, Park YS, Jeon YK, Nam SJ, Huh J (2011) Comparison of plasma cell type of Castleman’s disease and IgG4-related sclerosing disease: a histopathological and immunohistochemical study. Pathobiology 78:227–232CrossRefPubMed
27.
Zurück zum Zitat Zen Y, Fujii T, Harada K et al (2007) Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 45:1538–1546CrossRefPubMed Zen Y, Fujii T, Harada K et al (2007) Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 45:1538–1546CrossRefPubMed
28.
Zurück zum Zitat Inoue D, Zen Y, Abo H et al (2009) Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 251:260–270CrossRefPubMed Inoue D, Zen Y, Abo H et al (2009) Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 251:260–270CrossRefPubMed
29.
Zurück zum Zitat Johkoh T, Muller NL, Ichikado K et al (1998) Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology 209:477–481CrossRefPubMed Johkoh T, Muller NL, Ichikado K et al (1998) Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology 209:477–481CrossRefPubMed
30.
Zurück zum Zitat Frizzera G, Peterson BA, Bayrd ED et al (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202–1216PubMed Frizzera G, Peterson BA, Bayrd ED et al (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202–1216PubMed
31.
Zurück zum Zitat Herrada J, Cabanillas F, Rice L, Manning J, Pugh W (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657–662CrossRefPubMed Herrada J, Cabanillas F, Rice L, Manning J, Pugh W (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657–662CrossRefPubMed
32.
Zurück zum Zitat Bowne WB, Lewis JJ, Filippa DA et al (1999) The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 85:706–717CrossRefPubMed Bowne WB, Lewis JJ, Filippa DA et al (1999) The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 85:706–717CrossRefPubMed
33.
Zurück zum Zitat Beck JT, Hsu SM, Wijdenes J et al (1994) Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602–605CrossRefPubMed Beck JT, Hsu SM, Wijdenes J et al (1994) Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602–605CrossRefPubMed
34.
Zurück zum Zitat van Rhee F, Fayad L, Voorhees P et al (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol 28:3701–3708CrossRefPubMed van Rhee F, Fayad L, Voorhees P et al (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol 28:3701–3708CrossRefPubMed
Metadaten
Titel
Assessment of Pathologically Diagnosed Patients with Castleman’s Disease associated with Diffuse Parenchymal Lung Involvement Using the Diagnostic Criteria for IgG4-Related Disease
verfasst von
Takaaki Ogoshi
Takashi Kido
Kazuhiro Yatera
Keishi Oda
Toshinori Kawanami
Hiroshi Ishimoto
Noriho Sakamoto
Arisa Sano
Chiharu Yoshii
Shohei Shimajiri
Hiroshi Mukae
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Lung / Ausgabe 6/2013
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9497-x

Weitere Artikel der Ausgabe 6/2013

Lung 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.